A Single Subcutaneous Dose of BMD-1141 Stimulates Hair Regrowth Comparable to Daily, High-Dose Ruxolitinib in a Mouse Model of Alopecia Areata.

BMD-1141 also showed a significant ( p < 0.05) increase in the number of anagen hair follicles compared to ruxolitinib after 8 weeks of treatment and showed a trend towards fewer dystrophic hair follicles.

also in 53,322 other papers

Results Treatment with BMD-1141 led to observable, dose-dependent increases in hair growth, as evaluated by the mean hair area, showing similar results to the ruxolitinib-treated group, at the expected therapeutic dose of 320 mcg/kg ( Figure 1 ), though the overall changes did not reach statistical significance, even in the high-dose ruxolitinib group; this is likely due to the substantial initial hair loss at the start of the study.

also in 111,027 other papers